)
Guardant Health (GH) investor relations material
Guardant Health Investor Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic vision and innovation
The Smart Platform and Infinity AI drive innovation by integrating multimodal data for oncology, screening, and multi-disease applications, supporting rapid clinical and regulatory advancement.
Shield platform expands from CRC to multi-cancer detection, with a national rollout, large-scale data collection, and real-world validation studies to support regulatory-grade evidence.
Biobank surpasses 1 million patient samples and 200+ PB of data, fueling Infinity AI for discovery, product upgrades, and development across 500+ diseases.
Strategic collaborations, including Quest Diagnostics and Pfizer, expand access, accelerate clinical utility studies, and support commercial scale.
Highlighted a succession of S-curves: therapy selection ($10B), MRD ($20B), cancer screening ($50B), and future multi-disease screening.
Product and business development
Guardant360 Liquid and Tissue, powered by the Smart Platform, lead the therapy selection market with rapid turnaround, comprehensive profiling, and 15+ smart apps; PMA submitted for further adoption.
Guardant Reveal is the leading tissue-free MRD solution, expanding with Reveal Ultra for ultrasensitive detection down to 1 ppm, launching soon.
Shield, the first FDA-approved blood test for CRC screening, achieved rapid adoption, >90% adherence, NCCN guideline inclusion, and is expanding to multi-cancer detection.
Strategic partnership with Quest Diagnostics will expand Shield's reach to 650,000 clinicians, with no expected ASP or margin impact.
Biopharma business, serving 190+ customers, grew 30% in 2024, delivers double-digit growth, and is expanding the CDx pipeline.
Financial guidance and targets
2025 revenue expected at $915M–$925M, with 24%–25% YoY growth; oncology up 20%, biopharma/data mid-teens, and screening $55M–$60M.
2028 revenue target raised to ~$2.2B (34% CAGR), driven by oncology ($1.4B), biopharma/data ($300M), and screening ($500M+).
Gross margin target increased to 65%–70% by 2028, supported by ASP increases, COGS reductions, and further automation.
Company-wide free cash flow breakeven pulled forward to Q4 2027, 12 months ahead of prior guidance.
Oncology and screening ASPs projected to rise, with Reveal targeting $1,000 and Guardant360 Liquid $3,300 by 2028.
Next Guardant Health earnings date
Next Guardant Health earnings date
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)